The historical rank and industry rank for Remus Pharmaceuticals's FCF Margin % or its related term are showing as below:
NSE:REMUS'
s FCF Margin % Range Over the Past 10 Years
Min: -0.92 Med: 3.36 Max: 20.09
Current: 0.42
During the past 7 years, the highest FCF Margin % of Remus Pharmaceuticals was 20.09%. The lowest was -0.92%. And the median was 3.36%.
NSE:REMUS's FCF Margin % is ranked worse than 59.32% of 118
companies
in the Medical Distribution industry
Industry Median: 1.06
vs NSE:REMUS: 0.42
Remus Pharmaceuticals FCF Margin % Related Terms
Remus Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, COR, CAH: FCF Margin % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a FCF Margin % of -0.63% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Remus Pharmaceuticals and its competitors. According to the industry distribution chart, Remus Pharmaceuticals ranks #70 out of 118 companies in the Medical Distribution industry, placing it in the top 59.3%.
Is Remus Pharmaceuticals' FCF Margin % too high?
Remus Pharmaceuticals' current FCF Margin % is -0.63%. Based on the distribution chart, Remus Pharmaceuticals ranks #70 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' FCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #70 out of 118 companies for FCF Margin %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 1.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 1.06, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median FCF Margin % is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current FCF Margin % is -0.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current FCF Margin % is -0.63%. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current FCF Margin % is -0.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
FCF Margin %: -0.63%
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
